Die Kosteneffektivität von Amlodipin in der Behandlung der koronaren Atherosklerose in Österreich
- First Online:
- Cite this article as:
- Lange, A.P. & Szucs, T.D. Pharmacoeconomics-Ger-Res-Articles (2003) 1: 39. doi:10.1007/BF03321554
- 2 Downloads
Cost-effectiveness of amlodipine in the treatment of coronary atherosclerosis in Austria
Public healthcare expenditure has steadily increased in the past years. Since financial resources are increasingly limited, medical treatments must be evaluated for their cost-effectiveness compared to alternative treatments. This is the only way to ensure that the financial resources are most cost-effectively employed.
The purpose of this study is to answer the following question: What can be claimed about the cost-effectiveness in Austria of a medical therapy employing the calcium antagonist amlodipine (Norvasc™,1 Pfizer) in patients with angiographically documented coronary heart disease?
Patients and methods
The cost-effectiveness of amlodipine in the treatment of coronary artery disease was analysed by applying the results of the already published double-blind, randomised, placebo-controlled Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT), conducted in the United States, to the Austrian healthcare system. Costs were based on the Austrian lump sum model 2003, which contains monetary values of 1999.
We took the perspective of the federal health insurance system.
Calculating the effectiveness shows that the amlodipine cohort provided an additional life expectancy of 0.112 years per patient compared to the placebo cohort over an observation period of 3 years. Additional discounted total cost of approximately € 1,563 can be calculated for a patient treated with amlodipine over 3 years. Cost-effectiveness of amlodipine treatment in Austria is approximately € 13,925 per life year gained. The validity of this result was substantiated through extensive sensitivity analyses.
The application of the calcium antagonist amlodipine in patients with coronary heart disease in Austria is cost-effective.